Posted by Michael Wonder on 17 Oct 2024
Acadia Pharmaceuticals announces Health Canada approval of Daybue (trofinetide) for the treatment of Rett syndrome
16 October 2024 - Daybue is the first and only therapy approved in Canada for the treatment of Rett syndrome, a rare, neurodevelopmental disorder.
Acadia Pharmaceuticals today announced that Health Canada has granted marketing authorisation of Daybue (trofinetide) for the treatment of Rett syndrome in adult and paediatric patients two years of age and older under the priority review process.
